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Available online 27 September 2018Background:Miltefosine has been used successfully to treat visceral leishmaniasis (VL) in India, but it was unsuc-
cessful for VL in a clinical trial in Brazil.
Methods: To identify molecular markers that predict VL treatment failure whole genome sequencing of
26 L. infantum isolates, from cured and relapsed patients allowed aGWASanalysis of SNPs, gene and chromosome
copy number variations.
Findings: A strong association was identiﬁed (p = 0·0005) between the presence of a genetically stable
L. infantum Miltefosine Sensitivity Locus (MSL), and a positive response to miltefosine treatment. The risk of
treatment failure increased 9·4-fold (95% CI 2·11–53·54) when an isolate did not have the MSL. The complete
absence of the MSL predicted miltefosine failure with 0·92 (95% CI 0·65–0·996) sensitivity and 0·78 (95% CI
0·52–0·92) speciﬁcity. A genotyping survey of L. infantum (n= 157) showed that the frequency of MSL varies
in a cline from 95% in North East Brazil to b5% in the South East. The MSL was found in the genomes of all
L. infantum and L. donovani sequenced isolates from the Old World (n = 671), where miltefosine can have a
cure rate higher than 93%.
Interpretation:Knowledge on the presence or absence of theMSL in L. infantumwill allow stratiﬁcation of patients
prior to treatment, helping to establish better therapeutic strategies for VL treatment.
Fund: CNPq, FAPES, GCRF MRC and Wellcome Trust.logy and In
gton, York
logy and In
gton, York
rnielli),
. This is an© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
Visceral leishmaniasis
Miltefosine treatment failure
Whole-genome sequencing
Miltefosine Susceptibility Locus
Prognostic marker1. Introduction
Visceral leishmaniasis (VL) is a neglected of tropical diseases that
is endemic in N65 countries, with major foci in the Indian subconti-
nent, East Africa and Latin America. VL has a case-fatality rate of
~10% from an estimated 200,000–400,000 cases per year. VL is thefection, Department
YO10 5DD, United
fection, Department
YO10 5DD, United
open access article undermost severe form of a complex of leishmaniasis diseases and is
caused by Leishmania donovani and L. infantum (synonymy with
L. chagasi) [1]. The number of cases of VL in the Indian subcontinent
is decreasing and elimination has been seen as achievable with effec-
tive deployment of existing control measures [2], although challenges
remain [3]. VL in Brazil is a zoonotic disease caused by L. infantum,
with the dog as the primary reservoir. Brazil reports around 3000
new case of VL a year; the disease was originally restricted to remote
rural areas in Brazil, but has now become prevalent in urban centers,
greatly enhancing the population at risk of infection especially in im-
munodeﬁcient individuals [1,4].
VL treatment relies on a few available drugs and in Brazil ﬁrst line
treatment is a 20-day course of meglumine antimoniate (20 mg
Sb5+/kg/day), with liposomal amphotericin B (3 mg/kg/day forthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Research in context
Evidence before this study
Miltefosine has been usedwith success to treat visceral leishman-
iasis caused by L. donovani on the Indian subcontinent. However,
the clinical trial conducted in Brazil resulted in about 40% of pa-
tients with L. infantum infection relapsing after the miltefosine
treatment. Previouswork has demonstrated thatmiltefosine resis-
tance can be selected easily in vitro. These Leishmania laboratory
lines have been used to understand the molecular basis of
miltefosine resistance; however, studies using field isolates with
different responses to miltefosine are still needed to understand
the underlying mechanism in natural populations of Leishmania.
Added value of this study
This study generated genome sequences of 26 L. infantum iso-
lates, obtained from patients with different miltefosine treatment
outcomes. This provides extensive information on genomic varia-
tion (SNPs, InDels, and gene and chromosome copy number vari-
ation) unique to the parasites of Brazil including a new molecular
marker of miltefosine treatment failure (MSL). The MSL contains
four genes (3′-nucleotidase/nucleases LinJ.31.2370 and
LinJ.31.2380; helicase-like protein LinJ.31.2380; and 3,2-trans-
enoyl-CoA isomerase LinJ.31.2400). TheMSL has not been iden-
tified in any studies where miltefosine resistance has been gener-
ated in Leishmania in the laboratory.
Implications of all the available evidence
Our genomic analysis showedMSL as a potential molecular mark-
er to predict miltefosine treatment outcome in visceral leishmania-
sis. Ourwork highlights the importance of genotyping this locus in
Leishmania field isolates to contribute to the rational use of
miltefosine and design new therapeutic strategies for the treat-
ment of VL.
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being second line treatments [5]. There are no new drugs in clinical
trials and in light of increasing treatment failure [6] efforts are cur-
rently focussed on improving current treatments with the available
drugs, including in combinations [7]. The identiﬁcation of an effective
and safe oral drug, miltefosine (hexadecylphosphocholine), was an
important advance in leishmaniasis therapy [8]. Miltefosine was the
ﬁrst oral drug approved for VL treatment in India [9,10]. While
miltefosine was able to produce a clinical cure in about 94% of VL
caused by L. donovani when ﬁrst introduced in India [9,10], a phase
2 dose-ranging trial in Brazil showed that the cure rate was much
lower (~60%). The reason for the low cure rate is unknown, but
may be associated with a natural resistance to miltefosine within
the circulating population of L. infantum in Brazil. Whilst resistance
to miltefosine is easily generated in the laboratory, and some resis-
tance mechanisms have been determined [11–14], the molecular
basis involved in miltefosine treatment failure are required, so that
diagnostic markers can be developed to inform clinical practice. The
purpose of this genome-wide association study (GWAS) was to in-
vestigate the L. infantum genomic variation associated with
miltefosine treatment failure in Brazil. We pinpoint new molecular
components that correlate with miltefosine treatment failure and
that can be used in clinical settings to establish the best therapeutic
strategies for VL treatment.2. Materials and methods
2.1. Study design, patients and parasites
The genome-wide association (GWA) study, designed to identify ge-
netic markers of miltefosine treatment failure, was performed with 26
pre-treatment L. infantum isolates (14 from cured and 12 from relapsed
patients) recovered out of the 42 VL patients enrolled in the clinical trial
designed to evaluate the efﬁcacy and toxicity ofmiltefosine in treatment
of VL in Brazil (Montes Claros, Minas Gerais and Teresina, Piauí) in
2005–2007 (Fig. 1A). The patients were treated with 2·5 mg/kg/day of
miltefosine for 28 days (14 patients) or 42 days (28 patients), and
were followed for at least six months, but at most one year after treat-
ment. Patients were considered cured if no signs and symptoms of the
disease were present at the time of examination. Relapse was deﬁned
as a patient whowas considered cured, but upon follow-up, showed re-
appearance of clinical signs and positive parasitology. The protocol was
approved by the Comissão Nacional de Ética em Pesquisa (CONEP
D-18506-Z019) and are registered with ClinicalTrials.gov, number
NCT00378495. Ethical clearance, which was a waiver for informed con-
sent from patients, for utilization in research of the L. infantum isolates
obtained from patients enrolled in miltefosine Brazilian trial was ob-
tained from the institutional review board of the Centro de Ciências da
Saúde, Universidade Federal do Espírito Santo (CEP-066/2007), Brazil.
2.2. Genomic analysis
Genome sequencingwas performedwith paired-end Illumina reads.
Details of DNA preparation, sequencing, genotyping, and bioinformatics
analysis are described in the appendix and Fig. 1B. Brieﬂy, reads were
aligned to the resequenced L. infantum JPCM5 reference genome,
downloaded from http://leish-esp.cbm.uam.es version 1. Copy number
variations (CNV) at chromosomeandgene levelwere calculated accord-
ing to Rogers et al. [15], using OrthoMCL to assign genes to 7822 multi-
copy gene clusters (orthologous groups, OGs). Single nucleotide poly-
morphisms (SNPs) and small insertion-deletion polymorphism
(InDel) calls were generated by GATK HaplotypeCaller [16] and
Freebayes [17], accepting only variants called by both callers.
CNVs may be unstable within hosts and/or within culture [18]. To
examinewhether theywere sufﬁciently stable to be useful as prognostic
markers we estimated the heritability of these 7822 OGs, using a re-
stricted maximum likelihood method (REML) implemented in LDAK
[19], using a kinship matrix derived from SNPs and InDels. OGs that
were inherited in a stable manner with SNPs (n = 757) were deﬁned
as those whose heritability was two standard deviations above zero.
GWAS to test for associations between OGs and treatment outcome
were performedwith the 757 stable OGs using custom R scripts. Associ-
ations were detected using Mann-Whitney tests, corrected for multiple
tests by permuting the cure/relapse trait.
Genome-wide association analyses were performed using SNPs and
InDels to test for statistical associations withmiltefosine treatment out-
come using LDAK [19], with the 1752 variants that had a minor allele
count N1. The SNP and InDel kinshipmatrix as abovewasused to control
for unequal relatedness of strains. We estimated the P-value threshold
by permuting the cure/relapse trait for individuals 1000 times, record-
ing the lowest P-value, and using the 5% quantile (50th lowest value)
of these values as the threshold. Variants passing this threshold (4.7
× 10−6) therefore had a 5% error rate.
2.3. Genetic analysis of the MSL locus
For technical validation of NGS data, PCR ampliﬁcation of theMSL on
chromosome 31 was accomplished according to PCR strategy shown in
Fig. 2A and supplementary table 1. The geographic distribution of MSL
geneticmarker highlighted byGWASwas investigated in the 26 isolates
from the miltefosine trial and in another 131 L. infantum isolates from
Fig. 1. Flow charts of phase-two Brazilian miltefosine trial and L. infantum parasites recovered from enrolled patients (A), and the key steps used in the bioinformatics analysis (B). SNPs,
Single Nucleotide Polymorphisms; InDels, Insertions and Deletions; CNV, Copy Number Variation; GWAS, Genome-Wide Association Study.
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diagnostic process in Brazil; and by analysis of 20 whole-genome para-
site sequences available on Sequence Read Archive (SRA, https://www.
ncbi.nlm.nih.gov/sra). The MSL frequency was also determined in
L. infantum or L. donovani from the Old World, using 671 whole-
genome parasite sequences on the SRA.
Correlation between complete absence of MSL and miltefosine
treatment failure was assessed by contingency table analysis (Fisher's
exact test). Relative risk and Sensitivity/Speciﬁcity were estimated
using the Koopman asymptotic score and Wilson-Brown tests,
respectively.2.4. Homogeneity of L. infantum clinical isolates
A number of isolates from the miltefosine trial showed heteroge-
neous MSL genotypes by PCR. To resolve these all heterogeneous
samples (n = 7) and homogeneous controls (n = 3) were cloned,
and re-screened for the MSL presence. The cloning, genomic DNA ex-
traction, and MSL screening processes are described in the appendix.
The natural mechanism of MSL deletion was investigated by cloning
and sequencing the MSL ﬂanking sequence in 21 L. infantum MSL−
or MSL+/− isolates.3. Results
A phase 2 dose-ranging trial to assess efﬁcacy and safety of orally ad-
ministered miltefosine in patients with VL in Brazil followed 42 pa-
tients: 14 from Montes Claros–MG and 28 from Teresina–PI sites
(Fig. 1A and Table 1). In Montes Claros, a standard dose and treatment
length of 2·5 mg/Kg/day, with the maximum dose of 100 mg/day, for
28 days was used. All patients from Montes Claros presented initial
cure, although eight relapsed after the treatment, showing a ﬁnal cure
rate of 43%. Because of the high relapse rate observed in Montes Claros
an extended treatment of 42 dayswith the same dosewas carried out in
Teresina. In this site two patients did not respond to the miltefosine
treatment and from the others who presented initial cure seven re-
lapsed after the treatment, resulting in a ﬁnal cure rate of 68%. These
data together revealed a cure rate of ~60% in these two Brazilian regions,
lower than that found for Indian VL when miltefosine was ﬁrst used in
India (N90%) [9,10,20]. The cure rate between the pediatric and the
adult patients did not exhibit a signiﬁcant difference (treatment failure
rate of 52·2% [12/23] and 26·3% [5/19] in pediatric and adult patients,
respectively, with Chi-square p= 0·09).
To investigate the molecular basis of miltefosine treatment failure
genome sequences were obtained from 26 pre-treatment L. infantum
isolates (Table 1). Comparison to the Spanish reference strain
Fig. 2. Technical validation of bioinformatics data of structural variation. (A) PCR strategy to verify the presence of miltefosine sensitivity locus (MSL) and their genes individually:
LinJ.31.2370, LinJ.31.2380, LinJ.31.2390 and LinJ.31.2400. (B) Results of PCR reaction presented in “A”. The * highlights the L. infantum isolates from cured patients that showed mixed
genetic proﬁle for the presence of MSL, and were subsequently cloned. The ^ highlights the L. infantum isolates used as controls for the cloning process. The presence of the complete
MSL in the L. infantum genome is demonstrated by a PCR product of ~14 kb, whilst loss is demonstrated by a ~1·2 kb DNA fragment.
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SNPs. Excluding variants that were ﬁxed in all Brazilian isolates (that
represent differences between the Brazilian population and the Spanish
reference), left 1969 variants that were polymorphic within Brazilian
isolates (413 InDels; 1535 SNPs; and 21 others) (Table 2 and Supple-
mentary Table 2).This relatively small number of variants made GWAS analysis feasi-
ble, because it reduced the statistical burden of multiple test correction.
Genome-wide association analysis was performed using these 1969
variants and clinical data to associate variants with relapse/cure treat-
ment outcomes. The minimum association P-value was 3.1 × 10−3. As
this did not pass the empirical P-value threshold of 4.7 × 10−6 we
Table 1
Clinical proﬁles of the VL patients treated with miltefosine and genome sequencing summary.
Isolate ID Locationa Treatment lengthb (days) Clinical outcome Presence of MSLc Coverage fold Mappingd (%)
MHOM/BR/06/MA01A Paraibano-MA 42 Cure + 66·2 98·89
MHOM/BR/05/MA02A Codó-MA 42 Cure +/− 66·8 99·06
MHOM/BR/06/MA03A Timon-MA 42 Cure + 91·2 98·72
MHOM/BR/06/MA04A Codó-MA 42 Cure − 46·9 98·85
MHOM/BR/05/MA05A Timon-MA 42 Cure +/− 41·3 98·98
MHOM/BR/06/MA07A Caxias-MA 42 Relapse − 27·1 98·94
MHOM/BR/05/MG11A Montes Claros-MG 28 Relapse − 75·1 98·67
MHOM/BR/05/MG12A Montes Claros-MG 28 Cure − 43·4 98·87
MHOM/BR/05/MG13A São Francisco-MG 28 Relapse − 47·5 99·15
MHOM/BR/05/MG14A Montes Claros-MG 28 Cure + 57·7 98·99
MHOM/BR/05/MG15A Porteirinha-MG 28 Relapse − 64·5 98·74
MHOM/BR/05/MG16A São Francisco-MG 28 Relapse − 83·5 98·99
MHOM/BR/05/MG17A Montes Claros-MG 28 Relapse − 65·1 98·83
MHOM/BR/05/MG18A Montes Claros-MG 28 Relapse − 48·6 98·54
MHOM/BR/05/MG19A Catuni-MG 28 Cure − 56·3 98·44
MHOM/BR/06/PI01A José de Freitas-PI 42 Relapse − 92·7 98·95
MHOM/BR/06/PI02A Valença do Piauí-PI 42 Relapse − 60·0 98·63
MHOM/BR/06/PI03A Cabeceiras-PI 42 Relapse − 65·3 98·57
MHOM/BR/05/PI04A Valença do Piauí-PI 42 Cure +/− 46·7 98·82
MHOM/BR/06/PI05A Valença do Piauí-PI 42 Cure +/− 41·3 99·02
MHOM/BR/06/PI07A Piripiri-PI 42 Cure + 47·1 99·03
MHOM/BR/05/PI08A Altos-PI 42 Cure +/− 46·1 99·07
MHOM/BR/05/PI09A Nova Santa Rita-PI 42 Cure +/− 57·8 99·01
MHOM/BR/06/PI10A Teresina-PI 42 Cure +/− 76·9 98·63
MHOM/BR/06/PI11A José de Freitas-PI 42 Relapse − 42·2 98·94
MHOM/BR/05/PI12A Lima Campos-PI 42 Relapse + 58·6 98.68
a City-States in Brazil where the L. infantum isolates were collected: MA, Maranhão; MG, Minas Gerais; PI, Piauí.
b Miltefosine therapy schedule. Patients received about 2·5 mg/kg/day.
c Genotyping of L. infantum isolates : MSL+, homogeneous population for presence of MSL; MSL−, homogeneous population for absence of MSL;MSL+/−, heterogeneous population for
presence of MSL.
d Mapping of sequences reads from L. infantum isolates to L. infantum JPCM5 reference genome.
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cure/relapse. Whole-chromosome copy number analysis revealed dif-
ferent degrees of ploidy due to the high plasticity of L. infantum (Supple-
mentary Fig. 1). As with the small variants (SNPs and InDels), theTable 2
Summary of genetic variants identiﬁed in L. infantum isolates from cure and relapse patients.
Variants in 26 L. infantum
sequenced genomes
Variable CNVs between cure and relapse (12 OGs with lowes
Ortholog
Group
Gene ID Chra Product Descr
SNP sites 16268 OG5_183927 LinJ.31.2390 LinJ.31 helicase-like
Monomorphic
SNPs
11,010 OG5_183871 LinJ.31.0050 LinJ.31 MFS/sugar tra
Monomorphic
InDels
5755 OG5_128720 LinJ.31.2370,
LinJ.31.2380
LinJ.31 3′-nucleotida
3′-nucleotida
putative
SNPs 5258 OG5_148411 LinJ.14.1300 LinJ.14 hypothetical
MNPs 20 OG5_133169 LinJ.34.3390 LinJ.34 complex 1 pr
putative
Others 30 OG5_145899 LinJ.13.0890 LinJ.13 hypothetical
Segregating
variants
1969 OG5_140412 LinJ.31.3090 LinJ.31 hypothetical
Variant sites 1969 OG5_148059 LinJ.19.0630 LinJ.19 histone H3 va
InDels 413 OG5_171427 LinJ.01.0840 LinJ.01 potassium ch
protein
SNPs 1535 OG5_148814 LinJ.28.0780 LinJ.28 hypothetical
MNPs 18 OG5_148000 LinJ.01.0070 LinJ.01 BSD domain c
putative
Others 3 OG5_184157 LinJ.36.4130 LinJ.36 hypothetical
function
MNPs, Multiple Nucleotide Polymorphisms. SNPs, Single Nucleotide Polymorphisms. InDels, I
InDels correspond to common variants to all brazilian L. infantum isolates analysed here.
a Chr, chromosome.
b Ref Hap., haploid copy number in reference L. infantum JPCM5.
c Mann-Whitney p, P-value of Mann-Whitney analysis.
d Perm. p, P-value after permutation analysis.diversity in whole-chromosome copy number was not able to distin-
guish the isolates from cured and relapsed VL patients and did not seg-
regate with any other property of these samples such as geographic
location.t p-values)
iption Ref
Hapb
Mean – Gene
Dosage
Heritability Mann
Whitney
P-valuec
Perm.
p-valued
Cure
Group
Relapse
Group
protein 1 2·97 0·33 1·00 0·00 0·0005
nsport protein, putative 1 3·46 4·04 1·00 0·00 0·0013
se/nuclease, putative 2 5·38 0·72 1·00 0·00 0·0015
se/nuclease precursor,
protein, conserved 1 2·33 1·92 1·00 0·00 0·0033
otein (LYR family), 1 2·39 1·05 1·00 0·01 0·0046
protein, conserved 1 2·62 1·99 1·00 0·01 0·007
protein, conserved 1 3·76 4·29 1·00 0·01 0·0074
riant V 1 0·56 3·20 1·00 0·01 0·0077
annel subunit-like 1 1·96 1·75 1·00 0·01 0·0078
protein, conserved 1 0·85 2·19 1·00 0·01 0·0087
ontaining protein, 1 2·18 1·79 1·00 0·01 0·0088
protein, unknown 1 2·16 1·83 1·00 0·01 0·0093
nsertions and Deletions. Others, variants not covered in the table. Monomorphic SNPs or
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ﬁed 59 that exhibited a signiﬁcant difference in gene dose between
the pre-treatment isolates from the cured and relapsed groups (p b
0·05, Mann-Whitney tests, permutation-corrected) (Supplementary
Tables 3). Themost signiﬁcantly associatedOG and two other highly sig-
niﬁcantly OGswere located in a 12·7 kb region on supernumerary chro-
mosome 31 (the miltefosine sensitivity locus, MSL), which was present
in the majority of isolates from cured patients, but absent in almost all
isolates from relapsed patients (Fig. 2 and Supplementary Fig. 2).
The MSL contains four genes, two of which are tandem duplicates
(LinJ.31.2370 and LinJ.31.2380, encoding for 3′-nucleotidase/nuclease,
putative). LinJ.31.2390 (encoding for helicase-like protein) is a single-
copy gene with no paralogues outside of the cluster, whilst
LinJ.31.2400 (encoding for 3,2-trans-enoyl-CoA isomerase,mitochondri-
al precursor, putative) has a paralog upstreamof theMSL (LinJ.31.2320).
The gene dosage for the MSL locus was between 1·5–2·3, which is
lower than expected for genes on a tetraploid chromosome and is pos-
sibly due to the presence of mixed populations in the isolates (see
below). The dosage of all orthologous groupswithin theMSLwere high-
ly heritable (heritability N90%), indicating that gene+ dosages segre-
gate consistently with the SNPs, rather than ﬂuctuating rapidly within
the population, or within culture (Supplementary Table 3, Supplemen-
tary Fig. 3). The MSL is a genetically stable, variable gene copy number
marker that is strongly associated with treatment outcome (Supple-
mentary Table 3, supplementary Fig. 3). The presence of the MSL locus
in the 26-sequenced L. infantum isolates was technically validated by
PCR, which conﬁrmed the genome sequencing data (Fig. 2). Fisher's
Exact test revealed that there is a very strong association (p =
0·0005) between the presence of the MSL in the L. infantum genome
and cure with miltefosine treatment, with a reciprocal relative risk of
9·43 (95% CI 2·11 to 53·54) to treatment failure when an isolate has
a complete deletion of the MSL.
The PCR analyses revealed that seven L. infantum isolates (MA02A,
MA05A, PI04A, PI05A, PI08A, PI09A and PI10A) from cured patients ex-
hibited amixed genomic proﬁle, producing bothMSL+ andMSL− prod-
ucts, consistent with a reduced gene dose observed in the sequencing
data for these isolates. To determine whether the heterogeneity result-
ed from loss of MSL on some chromosomes in individual cells or wheth-
er the population was a mix of genotypes, these isolates were cloned
and analysed for the presence of the MSL. In addition, three isolates in
which heterogeneity was not observed in the initial screen (MA01A,
MG11A and MG14A) were cloned and analysed. This revealed that all
the cloned cells were either MSL+ or MSL− (Supplementary Fig. 4),
showing that the observed heterogeneity is due to a mix of genotypes
in the original isolate. However, in some of the clones PCR analysis re-
vealed a low intensity DNA fragment at ~1·2 kb in addition to the
more prominent MSL DNA fragment at 14 kb. This DNA fragment was
extracted and sequenced, revealing the novel junction formed after
MSL deletion. It can be inferred that loss of an allele of the MSL can
occur at low level within individual cells in a culture population.
Themechanism of MSL loss from L. infantumwas investigated by se-
quencing the novel junctions formed after deletion of this locus. This re-
vealed that the deletion occurred in exactly the same position for all
isolates (Supplementary Fig. 5). The novel junction formed when the
MSL is excised corresponds to the repetitive elements that make up
the repeat alignment group RAG337 described by Ubeda et al. [21].
We can speculate that deletion of the MSL occurred by homologous re-
combination using repetitive sequence ﬂanking the locus (Fig. 3), and
that it rose to the relatively high frequency we observe in Brazil either
by genetic drift or by selection for some trait other than miltefosine
pressure.
To estimate the percentage of L. infantum parasites that might re-
spond to treatment with miltefosine in different regions of Brazil, 131
more L. infantum isolates were screened for the presence of the MSL
(Fig. 4). Overall, 43% of these L. infantum isolates contained the MSL.
The prevalence of the MSL was highest in states of the Northeast ofBrazil, including Piauí, Maranhão and Rio Grande do Norte (74%),
whereas isolates from the states of Espírito Santo, Minas Gerais and
Bahia had a low MSL frequency (0%, 5% and 25%, respectively). In con-
trast theMSLwas found in publically available whole genome sequence
data for 671 Old World L. donovani/L. infantum isolates. In the vast ma-
jority of these Old World isolates, the gene dose for LdBPK_312390
(the orthologue of LinJ.31.2390) is close to 4, which is as expected for
this tetrasomic chromosome. The same pattern was observed for
LdBPK_312380. Complete loss of these two genes together as described
in L. infantumwas not observed in the 671 genomes analysed, suggest-
ing that the loss of the MSL locus occurred within Brazil.
4. Discussion
The genome-wide study with 26 New World Brazilian L. infantum
isolates revealed 16,268 small genetic variants. Of these, 11,010 SNPs
are present in all these Brazilian isolates, but are different from the
Spanish Old World reference strain JPCM5. The low genetic diversity
within Brazil suggests that these isolates are a recent population, in
agreement with a relatively recent Old World origin of New World
L. infantum [22]. The resistance to miltefosine observed in vitro has
been proposed to occur via changes in membrane permeability [14] or
a decrease in intracellular drug accumulation [23]. In contrast, our
study did not associate any individual SNP or InDel with miltefosine
treatment failure, including in genes that code for themiltefosine trans-
porter (LinJ.13.1590) and its β-subunit Ros3 (LinJ.32.1040), which have
been associated with resistance to miltefosine in Leishmania spp. in-
duced in vitro [11], and reported once in a L. infantum clinical isolate
[24]. The absence of genetic variation in the miltefosine transporter in
L. infantum isolates characterized here indicate that the genetic basis
of miltefosine resistance induced in vitro are not responsible for
miltefosine treatment failure in Brazil. It would be informative to carry
out a prospective study using PCR detection of the MSL to predict
miltefosine treatment outcome, but the drug is not currently licensed
for use in Brazil.
The genome analysis revealed the large extent of chromosome and
gene copy number variation among the L. infantum isolates. These
data corroborate previous ﬁndings, which have established variable
degrees of aneuploidy in strains and species of Leishmania grown in cul-
ture and in animal models of infection [15,25,26]. Although aneuploidy
in Leishmania ssp. parasites has been observed previously in drug resis-
tance selected in promastigotes in vitro [27,28], ourﬁndings support the
lack of correlation between aneuploidy and miltefosine treatment fail-
ure of clinical isolates [29]. It is likely that some aneuploidy variation
arises through culture of promastigote parasites derived from the clini-
cal isolates, as well as change in parasite's environment [18], complicat-
ing the analysis. Together with aneuploidy, gene ampliﬁcation by
expansion and contraction of genes in tandem arrays and by generation
of extrachromosomal elements also contributes to gene-dosage ﬂuctua-
tion. In Leishmania parasites, which lack regulated transcription, these
gene ampliﬁcations function as a mechanism to increase gene expres-
sion [18]. Variation in gene dose has also been associated with drug re-
sistance in Leishmania parasites induced in vitro [21,28], and naturally
found in ﬁeld [25], although for the ﬁrst time, we document the gene
dosage ﬂuctuation associated with miltefosine treatment failure in VL
caused by L. infantum.
In our study, 59 gene arrays, including genes contained within MSL,
exhibited a signiﬁcant difference in gene dosage (p b 0·05) between
isolates from cured and relapsed patients. These loci all demonstrated
high heritability (N0·95), indicating stable inheritance with SNPs.
Genes from the MSL locus were the most signiﬁcantly associated with
treatment outcome. Patients infected with an MSL+ or MSL+/−
L. infantum isolate will likely respond to treatment with miltefosine,
whilst those infected with MSL− have 9·4 fold greater risk of relapsing
after miltefosine treatment. The MSL locus was not completely predic-
tive of outcome, indicating that there are other parasite genetic,
Fig. 3. Identiﬁcation of repeated sequences ﬂanking MSL in the Leishmania genome and possible mechanisms for MSL loss. (A) Position of repeats sequences on chromosome 31 of
L. infantum JPCM5, identiﬁed by sequence of novel junction formed after MSL deletion in L. infantum isolates, (upper map). Repetitive elements with N90% identity to the L. infantum
RAG337 can be found in equivalent positions on chromosome 31 of L. donovani BPK282A1 and ﬂank a region that is syntenic with the MSL (lower map). (B) Model for loss of the MSL:
Homologous recombination between two direct-repeat sequences ﬂanking the MSL (RAG337–1′ and RAG337–2′), leading to formation of a circular extrachromosomal element.
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study is too small to detect subtle parasite genetic factors. Furthermore,
the presence of a mixed population (MSL+ /MSL−) in some clinical iso-
lates from cured patients hints at a possible ﬁtness cost for MSL− para-
sites when in the presence of MSL+ parasites following miltefosine
treatment.
The MSL deletion process most likely occurs by homologous
recombination using the direct repetitive sequence SIDER2 (Short
Interspersed DEgenerate Retroposon) [21] that ﬂanks the MSL. This
repeat sequence is widely distributed in the Leishmania spp. genome,
continuously undergoes rearrangement and is known to play a role
in post-transcriptional control of gene expression [21,30]. The herita-
bility analysis, however, suggests that the MSL locus is relatively sta-
ble within these regions of Brazil. Thus, isolates that contain the MSL
locus maintain it within the population, whereas once the MSL islost, the locus remains absent, and is not readily reintroduced into
the population. Our genome analysis of 671 Old World L. donovani
and L. infantum isolates revealed the presence of MSL in all strains,
indicating that the MSL locus is also relatively stable in these regions.
The frequency of the MSL locus varies considerably within Brazil. In
the south east (Espírito Santo and Minas Gerais), the locus is rare
(4·4% are MSL+), whereas in northeast region (Rio Grande do
Norte, Maranhão and Piauí) 74·1% of isolates are MSL+. We would
expect that miltefosine efﬁcacy would differ geographically, and
miltefosine will be more a effective treatment of VL patients in
Northeast Brazil.
In summary, a simple PCR test for the MSL allows the prediction of
miltefosine treatment outcome in VL patients infected by L. infantum,
allowing the establishment of more appropriate and personalized
drug treatment for visceral leishmaniasis in Brazil.
Fig. 4. Geographical distribution ofMSL in L. infantum circulating in different regions of Brazil. ES, Espírito Santo; MG,Minas Gerais; BA, Bahia; MA,Maranhão; PI, Piauí; RN, Rio Grande do
Norte.
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